Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, announces the launch of three novel IVD IHC antibody markers at the forefront of clinical diagnostic and research applications. These three markers SMAD4 [EP618Y], BAP1, and BCA-225 [Cu-18] may aid pathologists in critical prognostic and diagnostic decisions – impacting patient outcome. Each new marker is available as an IVD grade antibody in ready to use and concentrated formats, leveraging maximum flexibility for your laboratory.

BAP1 Antibody – Biocare’s rabbit polyclonal BAP1 is an excellent biomarker that may aid in diagnosis of multiple types of cancers including uveal melanoma, malignant mesothelioma, cutaneous melanoma, and renal cell carcinoma. Protein expression of BAP1 using immunohistochemistry may serve as a rapid and cost-effective means of identifying uveal melanoma patients with aggressive disease.1 Loss of BAP1 staining is associated with higher risk for tumor growth and metastasis.2

BCA-225 [Cu-18] Antibody – Biocare’s mouse monoclonal offering of BCA-225 is a well known clinical marker for breast carcinomas. BCA-225 expression was found to be common in adenocarcinomas of the breast (98%).3 Adenocarcinoma that metastasizes from an unknown primary site is a significant oncologic problem. When used in a panel, BCA225 may serve as a predictive marker to identify tumors of unknown origin.4

SMAD4 [EP618Y] Antibody – Biocare’s rabbit monoclonal offering of SMAD4 [EP618Y] may aid prognosis through varying expression. Loss of SMAD4 correlated significantly with decreased survival in all colon cancer patients. High SMAD4 expression, however, was significantly associated with increased survival, especially in colon cancer patients. SMAD4 loss, and to a lesser extent weak expression, is strongly associated with poor survival regardless of stage.5,6
The launch of these antibodies continue Biocare Medical’s long-standing history of providing novel, high-quality reagents to customers looking to advance their research and diagnostic efficiency in the laboratory. These new markers will provide a cost-effective expansion to pathologists looking to elevate clinical utility and diagnostic clarity.

About Biocare Medical
Biocare Medical is a global leader in solutions for cancer research and diagnostics, providing: world-class reagents, including tissue-conserving simultaneous Multiplex antibody cocktails and detections; renowned Customer Care; and a comprehensive suite of advanced instrumentation for IHC, molecular, and histology testing. Customers include clinical anatomic pathology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare’s reagent portfolio includes primary antibodies, Multiplex IHC, and FISH probes for target indications. Biocare also offers a unique line of polymer detections for clinical, human, and animal research that delivers high sensitivity and exceptionally low background. The Company’s advanced platforms of semi and fully-automated instrumentation have been designed to meet every need from high throughput clinical diagnostics to flexible research requirements. Biocare Medical’s corporate headquarters and operations are based in the San Francisco Bay Area with a global distribution network.

1. Shah, Akeesha A et al. “BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma.” Pathology vol. 45,7 (2013): 651-6. doi:10.1097/PAT.0000000000000002  2. See, Thonnie Rose et al. “BAP1 Immunoreactivity Correlates with Gene Expression Class in Uveal Melanoma.” Ocular oncology and pathology vol. 6,2 (2020): 129-137. doi:10.1159/000502550  3. Loy, T S et al. “Distribution of BCA-225 in adenocarcinomas. An immunohistochemical study of 446 cases.” American journal of clinical pathology vol. 96,3 (1991): 326-9. doi:10.1093/ajcp/96.3.326  4. Brown, R W et al. “Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site.” American journal of clinical pathology vol. 107,1 (1997): 12-9. doi:10.1093/ajcp/107.1.12  5. Isaksson-Mettävainio, Martin et al. “High SMAD4 levels appear in microsatellite instability and hypermethylated colon cancers, and indicate a better prognosis.” International journal of cancer vol. 131,4 (2012): 779-88. doi:10.1002/ijc.26473  6. Yan, Pu et al. “Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research vol. 22,12 (2016): 3037-47. doi:10.1158/1078-0432.CCR-15-0939

Email Cart